Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Is Selzentry effective for CCR5-tropic HIV?What is the price range for tigecycline generics?Does your insurance cover generic lipitor at any pharmacy?Is there a minimum order quantity for lipitor discounts?When can we anticipate xarelto's patent to expire?
See the DrugPatentWatch profile for Pomalyst
When Does Pomalyst Exclusivity Expire? Pomalyst (pomalidomide) is a medication used to treat multiple myeloma, a type of blood cancer [1]. The drug was first approved by the FDA in 2013. Exclusivity for Pomalyst, under the Hatch-Waxman Act, was scheduled to expire in 2018, eight years after its initial approval date [2]. According to data from DrugPatentWatch.com, the patent for Pomalyst, owned by Celgene (a Bristol Myers Squibb company), was set to expire in January 2028. This means that generic versions of the drug can enter the market after this date, and companies are no longer required to pay royalties to the patent holder [3]. Impact of Exclusivity Expiration The expiration of exclusivity will give companies the opportunity to develop generic versions of Pomalyst. This could lead to increased competition in the market for multiple myeloma treatments, potentially driving down prices and improving accessibility for patients [4]. However, pharmaceutical companies may also face new challenges in maintaining market share and profitability in an increasingly competitive landscape. What happens to Pricing and Accessibility? When generic versions of Pomalyst enter the market, prices are likely to decrease. However, the extent of this price drop is difficult to predict and may depend on various market factors. As a result, patients may benefit from increased accessibility to the medication, although the actual impact on prices and access may take time to unfold. Regulatory and Commercial Implications The expiration of exclusivity for Pomalyst marks a significant milestone for the pharmaceutical industry. As the market for branded multiple myeloma treatments becomes increasingly competitive, industry stakeholders will likely focus on maintaining market share, protecting intellectual property, and developing new treatments to address the needs of patients. References [1] National Institutes of Health. (2022). Pomalidomide. [2] Hatch-Waxman Act. (1984). Public Law 98-417. [3] DrugPatentWatch.com. (2023). Pomalyst (Pomalidomide) Patent Expiration. [4] Statista.com. (2022). Pharmaceutical market: Generic drug market share in the United States.